Every 8-K that Incyte Corp (INCY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow INCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INCY filings page.
INCYTE CORP (INCY) announced an agreement with the U.S. Centers for Medicare & Medicaid Services (CMS) aimed at improving patient access to its medicines while supporting continued U.S. biopharmaceutical innovation. Under this agreement, state Medicaid programs will be able to access Incyte’s products Jakafi and Jakafi XR at prices aligned with those in a defined group of other advanced, industrialized nations.
Incyte also expects that, under this arrangement, it will not be subject to certain future CMS pricing mandates, including the proposed GUARD and GLOBE models. The company stated that it does not expect this agreement to affect its 2026 financial guidance or have a material impact on its future financial outlook.
Incyte reported strong second quarter 2026 results, with total revenue of $1.67 billion, up 38% year over year, and total net sales of $1.49 billion, up 40%. Jakafi net sales were $817 million, up 7%. Opzelura net sales reached $450 million, up 173%, including a $246 million one-time, non-cash benefit from the CMS agreement; excluding this, total net sales grew 17%. Hematology and Oncology portfolio net sales rose 69% to $222 million. GAAP net income was $585.6 million and GAAP diluted EPS $2.81, while non-GAAP diluted EPS was $3.09. Cash, cash equivalents and marketable securities were $4.5 billion as of June 30, 2026.
Management updated 2026 guidance, raising total net sales to $5,130–$5,260 million from $4,770–$4,940 million, Opzelura net sales to $1,050–$1,100 million, and Hematology and Oncology net sales to $860–$890 million, reflecting the Opzelura CMS settlement’s estimated $300–$310 million incremental impact and continued portfolio growth. GAAP R&D and SG&A operating expense guidance increased to $4,915–$4,995 million (non-GAAP $4,625–$4,695 million), largely due to the Vega Therapeutics acquisition, including approximately $1,270 million of IPR&D expense and $50 million of additional R&D for latarcibart. The company also highlighted multiple late-stage trials and regulatory milestones across hematology, oncology and inflammation, including Jakafi XR’s U.S. approval, Monjuvi/Minjuvi submissions in newly diagnosed DLBCL, a positive CHMP opinion for Opzelura in moderate atopic dermatitis in Europe, and ongoing Phase 3 development of latarcibart in von Willebrand disease.
Incyte Corporation has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC, for an upfront payment of $1.25 billion. Star Therapeutics may receive up to an additional $750 million in sales milestone payments. The deal adds VGA039, an investigational monoclonal antibody in Phase 3 development for von Willebrand disease, to Incyte’s hematology portfolio and late-stage pipeline. VGA039 is being developed as a once-monthly subcutaneous prophylactic therapy and has received multiple U.S. FDA designations, including Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease. Incyte expects to record the transaction as a one-time R&D expense in its third-quarter and full-year 2026 GAAP and non-GAAP results.
Incyte Corporation has reached a settlement with the Centers for Medicare & Medicaid Services regarding how Medicaid rebate rules apply to Opzelura (ruxolitinib) cream. CMS will not treat Opzelura as a line extension of Jakafi for rebate purposes, and Incyte has withdrawn its related lawsuit. The company expects to record a one-time, non-cash benefit of approximately $246 million in the quarter ending June 30, 2026, reflecting reversal of accruals previously recorded through March 31, 2026. Incyte will stop accruing for potential line extension liabilities on Opzelura and anticipates better gross-to-net performance for the product going forward. The company plans to update its financial guidance to reflect the settlement in its next earnings release.
Incyte Corporation reported the results of its annual shareholder meeting held on June 8, 2026. Shareholders elected eight directors, including Julian C. Baker, Jean-Jacques Bienaimé, Otis W. Brawley, and others, each receiving substantially more “for” than “against” votes.
Shareholders also approved the compensation of the company’s named executive officers on a non-binding advisory basis, with 145,851,784 votes for, 28,078,013 against, and 290,891 abstentions, plus 11,426,181 broker non-votes. In addition, they ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 173,072,501 votes for, 12,457,655 against, and 116,713 abstentions.
Incyte Corporation has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront. Star Therapeutics may receive up to an additional $750 million tied to sales milestones, for total potential consideration of $2.0 billion subject to customary closing adjustments.
The deal adds VGA039, a first‑in‑class investigational monoclonal antibody in Phase 3 development for von Willebrand disease, to Incyte’s hematology portfolio. The equity acquisition is expected to close in the third quarter of 2026, pending Hart‑Scott‑Rodino review, and is expected to result in an approximate $1.25 billion R&D charge in Incyte’s third‑quarter and full‑year 2026 GAAP and non‑GAAP results.
Incyte Corporation reported strong first quarter 2026 results with double‑digit growth in sales and earnings. Total revenue reached $1.27 billion, up 21% from Q1 2025, driven by total net sales of $1.10 billion, a 20% increase.
Flagship cancer drug Jakafi generated net sales of $758 million, up 7%, while Opzelura cream grew 20% to $143 million. Hematology and oncology portfolio net sales more than doubled to $204 million, helped by rapid growth in Niktimvo, Monjuvi/Minjuvi and Zynyz.
GAAP operating income rose to $301.1 million and GAAP net income to $303.3 million, with diluted GAAP EPS of $1.47 and non‑GAAP diluted EPS of $1.81. The company ended the quarter with $4.0 billion in cash, cash equivalents and marketable securities and reaffirmed its 2026 guidance, including total net sales of $4.77–$4.94 billion. Management also highlighted late‑stage pipeline momentum, including 10 Phase 3 studies underway, positive Phase 3 results for povorcitinib in vitiligo, an accepted NDA in hidradenitis suppurativa and multiple anticipated approvals and launches from mid‑2026 into early 2027.
Incyte Corporation reported that Board member Susanne Schaffert has resigned from its Board of Directors. She notified the company on March 26, 2026, and her resignation will be effective April 15, 2026.
The company stated that her resignation was not due to any disagreement regarding its operations, policies, or practices, and the Board expressed appreciation for her service since 2022.
Incyte Corporation announced several executive leadership changes. Pablo J. Cagnoni was appointed President, Incyte and Global Head of Research and Development, adding broader enterprise-wide strategic and operational responsibilities while continuing to lead R&D. Steven H. Stein became Executive Vice President, Chief Medical Officer and Head of Late-stage Development, continuing to oversee late-stage programs in Hematology, Oncology and Immunology and Global Medical Affairs.
Mohamed Issa was appointed Executive Vice President and Head of U.S. Commercial, continuing to lead U.S. Oncology and taking on expanded responsibility for U.S. Immunology as these businesses are integrated into a single U.S. commercial organization. William J. Meury remains Chief Executive Officer and a member of the Board, while Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period. The filing states there were no changes to compensation arrangements for the impacted executives in connection with these title changes.
Incyte Corporation reported that on February 27, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter for the supplemental Biologics License Application for Zynyz (retifanlimab-dlwr) injection in metastatic non-small cell lung cancer in combination with platinum-based chemotherapy.
The FDA’s letter cited regulatory compliance inspection findings at Catalent Indiana, the third-party fill-finish facility referenced in the application, as the sole approvability issue. The FDA did not raise concerns about Zynyz’s efficacy, safety data in NSCLC, or the third-party drug substance manufacturer. Incyte is working with the FDA and Catalent Indiana to address the letter and support a potential resubmission.
Incyte reported strong growth for Q4 and full-year 2025 and set higher 2026 revenue targets. Total revenue reached $1.51 billion in the fourth quarter, up 28% year over year, and $5.14 billion for 2025, up 21%, driven mainly by a 20% increase in net product revenue to $4.35 billion.
Key brands Jakafi and Opzelura grew solidly, while newer oncology products Niktimvo and Zynyz contributed increasing sales. GAAP net income jumped to $1.29 billion for 2025, with diluted EPS of $6.41, reflecting both higher revenue and the absence of large one-time R&D charges recorded in 2024.
For 2026, Incyte guides total net product revenue to $4.77–$4.94 billion, including Jakafi of $3.22–$3.27 billion, Opzelura of $750–$790 million, and hematology/oncology products of $800–$880 million. The company also plans substantial R&D and SG&A investment while advancing multiple late-stage trials and preparing for potential new launches.
Incyte Corporation filed a current report stating that it has released financial results for its third fiscal quarter ended September 30, 2025. The company furnished the full text of its earnings press release as Exhibit 99.1, dated October 28, 2025. The report is presented as routine financial disclosure under the item covering results of operations and financial condition.
Incyte Corporation reported a leadership change in its finance organization. The Board of Directors appointed Thomas Tray, currently Vice President, Finance and Chief Accounting Officer, to also serve as the company’s principal financial officer, effective as of September 16, 2025.
Tray, age 48, has been with Incyte since 2005, starting as Manager of External Reporting and later serving as Vice President and Controller before his current roles. He holds a B.S. in Accounting from Mount Saint Mary’s University and an Executive MBA in Pharmaceutical Marketing from Saint Joseph’s University. The company states there are no special arrangements related to his appointment, no family relationships with directors or executive officers, and no material related-party transactions requiring disclosure.
In its Form 8-K dated June 26, 2025, Incyte Corporation (INCY) disclosed a major leadership transition.
Retirement of CEO Hervé Hoppenot: Mr. Hoppenot stepped down as President & Chief Executive Officer effective June 26, 2025, but will remain on the Board and act as special advisor for up to one year. Compensation during the advisory period equals his current $1,395,731 annual base salary for six months and 50% of that rate for the subsequent six months, plus a prorated 2025 cash bonus. He also received equity grants of 6,016 RSUs, 18,438 stock options, and 18,050 performance shares (0-200% payout, 3-year TSR goals), all of which will continue to vest post-transition, subject to customary covenants.
Appointment of William J. Meury as President & CEO: Effective the same date, Mr. Meury (age 57) joins the company and its Board. His background includes CEO roles at Anthos Therapeutics (2024-2025) and Karuna Therapeutics (2023-2024), senior commercial leadership at Allergan, and over 30 years in biopharma commercialization.
Compensation package for Mr. Meury: • Initial base salary $1,250,000 • Target annual bonus 100% of salary (pro-rated for 2025) • Time-based RSUs for 36,101 shares (25% per year over four years) • Options for 110,630 shares (25% after one year, then monthly over 36 months) • 108,303 performance shares (0-200% payout, 3-year TSR goals) • One-time sign-on PSU award for 125,000 shares (0-400% payout tied to multi-year stock-price hurdles) • Relocation and commuting benefits. Severance terms include 1.5× salary+target bonus if terminated without Cause or he resigns for Good Reason outside a change-of-control window, plus partial accelerated vesting of equity.
Governance changes: Lead Independent Director Julian C. Baker becomes Chairman of the Board.
These actions signal a planned but material shift in senior leadership, accompanied by significant equity-based incentives designed to align the incoming CEO with long-term shareholder value.